SABRIL SIDE EFFECTS
- Generic Name: vigabatrin oral solution
- Brand Name: Sabril
- Drug Class: Anticonvulsants, Other
SIDE EFFECTS
The following serious and otherwise important adverse reactions are described elsewhere in labeling:
- Permanent Vision Loss
- Magnetic Resonance Imaging (MRI) Abnormalities in Infants
- Neurotoxicity
- Suicidal Behavior and Ideation
- Withdrawal of Antiepileptic Drugs (AEDs)
- Anemia
- Somnolence and Fatigue
- Peripheral Neuropathy
- Weight Gain
- Edema
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In U.S. and primary non-U.S. clinical studies of 4,079 SABRIL-treated patients, the most common (≥5%) adverse reactions associated with the use of SABRIL in combination with other AEDs were headache, somnolence, fatigue, dizziness, convulsion, nasopharyngitis, weight gain, upper respiratory tract infection, visual field defect, depression, tremor, nystagmus, nausea, diarrhea, memory impairment, insomnia, irritability, abnormal coordination, blurred vision, diplopia, vomiting, influenza, pyrexia, and rash.
The adverse reactions most commonly associated with SABRIL treatment discontinuation in ≥1% of patients were convulsion and depression.
In patients with infantile spasms, the adverse reactions most commonly associated with SABRIL treatment discontinuation in ≥1% of patients were infections, status epilepticus, developmental coordination disorder, dystonia, hypotonia, hypertonia, weight gain, and insomnia.
Refractory Complex Partial Seizures
Adults
Table 1 lists the adverse reactions that occurred in ≥2% and more than one patient per SABRIL treated group and that occurred more frequently than in placebo patients from 2 U.S. adjunctive clinical studies of refractory CPS in adults.
Table 1: Adverse Reactions in Pooled, Adjunctive Trials in Adults with Refractory Complex Partial Seizures
Body System Adverse Reaction |
SABRIL dosage (mg/day) |
Placebo [N=135] % |
|
3000 [N=134] % |
6000 [N=43] % |
||
Ear Disorders | |||
Tinnitus | 2 | 0 | 1 |
Vertigo | 2 | 5 | 1 |
Eye Disorders | |||
Blurred vision | 13 | 16 | 5 |
Diplopia | 7 | 16 | 3 |
Asthenopia | 2 | 2 | 0 |
Eye pain | 0 | 5 | 0 |
Gastrointestinal Disorders | |||
Diarrhea | 10 | 16 | 7 |
Nausea | 10 | 2 | 8 |
Vomiting | 7 | 9 | 6 |
Constipation | 8 | 5 | 3 |
Upper abdominal pain | 5 | 5 | 1 |
Dyspepsia | 4 | 5 | 3 |
Stomach discomfort | 4 | 2 | 1 |
Abdominal pain | 3 | 2 | 1 |
Toothache | 2 | 5 | 2 |
Abdominal distension | 2 | 0 | 1 |
General Disorders | |||
Fatigue | 23 | 40 | 16 |
Gait disturbance | 6 | 12 | 7 |
Asthenia | 5 | 7 | 1 |
Edema peripheral | 5 | 7 | 1 |
Fever | 4 | 7 | 3 |
Chest pain | 1 | 5 | 1 |
Thirst | 2 | 0 | 0 |
Malaise | 0 | 5 | 0 |
Infections | |||
Nasopharyngitis | 14 | 9 | 10 |
Upper respiratory tract infection | 7 | 9 | 6 |
Influenza | 5 | 7 | 4 |
Urinary tract infection | 4 | 5 | 0 |
Bronchitis | 0 | 5 | 1 |
Injury | |||
Contusion | 3 | 5 | 2 |
Joint sprain | 1 | 2 | 1 |
Muscle strain | 1 | 2 | 1 |
Wound secretion | 0 | 2 | 0 |
Metabolism and Nutrition isorders | |||
Increased appetite | 1 | 5 | 1 |
Weight gain | 6 | 14 | 3 |
Musculoskeletal Disorders | |||
Arthralgia | 10 | 5 | 3 |
Back pain | 4 | 7 | 2 |
Pain in extremity | 6 | 2 | 4 |
Myalgia | 3 | 5 | 1 |
Muscle twitching | 1 | 9 | 1 |
Muscle spasms | 3 | 0 | 1 |
Nervous System Disorders | |||
Headache | 33 | 26 | 31 |
Somnolence | 22 | 26 | 13 |
Dizziness | 24 | 26 | 17 |
Nystagmus | 13 | 19 | 9 |
Tremor | 15 | 16 | 8 |
Memory impairment | 7 | 16 | 3 |
Abnormal coordination | 7 | 16 | 2 |
Disturbance in attention | 9 | 0 | 1 |
Sensory disturbance | 4 | 7 | 2 |
Hyporeflexia | 4 | 5 | 1 |
Paraesthesia | 7 | 2 | 1 |
Lethargy | 4 | 7 | 2 |
Hyperreflexia | 4 | 2 | 3 |
Hypoaesthesia | 4 | 5 | 1 |
Sedation | 4 | 0 | 0 |
Status epilepticus | 2 | 5 | 0 |
Dysarthria | 2 | 2 | 1 |
Postictal state | 2 | 0 | 1 |
Sensory loss | 0 | 5 | 0 |
Psychiatric Disorders | |||
Irritability | 7 | 23 | 7 |
Depression | 6 | 14 | 3 |
Confusional state | 4 | 14 | 1 |
Anxiety | 4 | 0 | 3 |
Depressed mood | 5 | 0 | 1 |
Abnormal thinking | 3 | 7 | 0 |
Abnormal behavior | 3 | 5 | 1 |
Expressive language disorder | 1 | 7 | 1 |
Nervousness | 2 | 5 | 2 |
Abnormal dreams | 1 | 5 | 1 |
Reproductive System | |||
Dysmenorrhea | 9 | 5 | 3 |
Erectile dysfunction | 0 | 5 | 0 |
Respiratory and Thoracic Disorders | |||
Pharyngolaryngeal pain | 7 | 14 | 5 |
Cough | 2 | 14 | 7 |
Pulmonary congestion | 0 | 5 | 1 |
Sinus headache | 6 | 2 | 1 |
Skin and Subcutaneous Tissue Disorders | |||
Rash | 4 | 5 | 4 |
Pediatrics 2 To 16 Years Of Age
Table 2 lists adverse reactions from controlled clinical studies of pediatric patients receiving SABRIL or placebo as adjunctive therapy for refractory complex partial seizures. Adverse reactions that are listed occurred in at least 2% of SABRIL-treated patients and more frequently than placebo. The median SABRIL dose was 49.4 mg/kg (range of 8.0 – 105.9 mg/kg).
Table 2: Adverse Reactions in Pooled, Adjunctive Trials in Pediatric Patients 3 to 16 Years of Age with Refractory Complex Partial Seizures
Body System Adverse Reaction |
All SABRIL [N=165] % |
Placebo [N=104] % |
Eye Disorders | ||
Diplopia | 3 | 2 |
Blurred vision | 2 | 0 |
Gastrointestinal Disorders | ||
Upper abdominal pain | 4 | 3 |
Constipation | 2 | 1 |
General Disorders | ||
Fatigue | 10 | 7 |
Infections and Infestations | ||
Upper respiratory tract infection | 15 | 11 |
Influenza | 7 | 3 |
Otitis media | 6 | 4 |
Streptococcal pharyngitis | 4 | 3 |
Viral gastroenteritis | 2 | 0 |
Investigations | ||
Weight gain | 15 | 2 |
Nervous System Disorders | ||
Somnolence | 6 | 5 |
Nystagmus | 4 | 3 |
Tremor | 4 | 2 |
Status epilepticus | 2 | 1 |
Psychiatric Disorders | ||
Abnormal behavior | 7 | 6 |
Aggression | 6 | 2 |
Disorientation | 3 | 0 |
Safety of SABRIL for the treatment of refractory CPS in patients 2 years of age is expected to be similar to pediatric patients 3 to 16 years of age.
Infantile Spasms
In a randomized, placebo-controlled IS study with a 5 day double-blind treatment phase (n=40), the adverse reactions that occurred in >5% of patients receiving SABRIL and that occurred more frequently than in placebo patients were somnolence (SABRIL 45%, placebo 30%), bronchitis (SABRIL 30%, placebo 15%), ear infection (SABRIL 10%, placebo 5%), and acute otitis media (SABRIL 10%, placebo 0%).
In a dose response study of low-dose (18-36 mg/kg/day) versus high-dose (100-148 mg/kg/day) SABRIL, no clear correlation between dose and incidence of adverse reactions was observed. The adverse reactions (≥5% in either dose group) are summarized in Table 3.
Table 3: Adverse Reactions in a Placebo-Controlled Trial in Patients with Infantile Spasms
Body System Adverse Reaction |
SABRIL Low Dose [N=114] % |
SABRIL High Dose [N=108] % |
Eye Disorders (other than field or acuity changes) | ||
Strabismus | 5 | 5 |
Conjunctivitis | 5 | 2 |
Gastrointestinal Disorders | ||
Vomiting | 14 | 20 |
Constipation | 14 | 12 |
Diarrhea | 13 | 12 |
General Disorders | ||
Fever | 29 | 19 |
Infections | ||
Upper respiratory tract infection | 51 | 46 |
Otitis media | 44 | 30 |
Viral infection | 20 | 19 |
Pneumonia | 13 | 11 |
Candidiasis | 8 | 3 |
Ear infection | 7 | 14 |
Gastroenteritis viral | 6 | 5 |
Sinusitis | 5 | 9 |
Urinary tract infection | 5 | 6 |
Influenza | 5 | 3 |
Croup infectious | 5 | 1 |
Metabolism & Nutrition Disorders | ||
Decreased appetite | 9 | 7 |
Nervous System Disorders | ||
Sedation | 19 | 17 |
Somnolence | 17 | 19 |
Status epilepticus | 6 | 4 |
Lethargy | 5 | 7 |
Convulsion | 4 | 7 |
Hypotonia | 4 | 6 |
Psychiatric Disorders | ||
Irritability | 16 | 23 |
Insomnia | 10 | 12 |
Respiratory Disorders | ||
Nasal congestion | 13 | 4 |
Cough | 3 | 8 |
Skin and Subcutaneous Tissue Disorders | ||
Rash | 8 | 11 |
Postmarketing Experience
The following adverse reactions have been identified during postapproval use of SABRIL. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions are categorized by system organ class.
Birth Defects: Congenital cardiac defects, congenital external ear anomaly, congenital hemangioma, congenital hydronephrosis, congenital male genital malformation, congenital oral malformation, congenital vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa, supernumerary nipple, talipes
Ear Disorders: Deafness
Endocrine Disorders: Delayed puberty
Gastrointestinal Disorders: Gastrointestinal hemorrhage, esophagitis
General Disorders: Developmental delay, facial edema, malignant hyperthermia, multi-organ failure
Hepatobiliary Disorders: Cholestasis
Nervous System Disorders: Dystonia, encephalopathy, hypertonia, hypotonia, muscle spasticity, myoclonus, optic neuritis, dyskinesia
Psychiatric Disorders: Acute psychosis, apathy, delirium, hypomania, neonatal agitation, psychotic disorder
Respiratory Disorders: Laryngeal edema, pulmonary embolism, respiratory failure, stridor
Skin and Subcutaneous Tissue Disorders: Angioedema, maculo-papular rash, pruritus, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), alopecia.
SRC: NLM .